Reported Earlier, China's NMPA Approves Astellas' VYLOY (Zolbetuximab) For Advanced Gastric Cancer Treatment

早前报道，中国国家药监局批准爱文思控股的VYLOY（Zolbetuximab）用于晚期胃癌治疗。

Benzinga · 01/06 00:55

- China has the highest number of cases and deaths from gastric cancer of any country worldwide1 -

- 中国是全球胃癌病例和死亡人数最多的国家1 -

- Zolbetuximab is the first and only therapy approved in China to target claudin 18.2, a biomarker expressed by 35% of Chinese patients with advanced gastric and gastroesophageal junction (GEJ) cancer2 -

- Zolbetuximab 是中国首个也是唯一一个批准用于靶向 claudin 18.2 的治疗，claudin 18.2 是35%的晚期胃癌和胃食管交界癌（GEJ）中国患者所表达的生物标志物2 -

- Treatment with the claudin 18.2-targeted monoclonal antibody shown to significantly extend both progression-free survival and overall survival in the Phase 3 GLOW and SPOTLIGHT trials3,4 -

- 在阶段3 GLOW 和 SPOTLIGHt 试验中，claudin 18.2 靶向单克隆抗体的治疗显著延长了无进展生存期和总体生存期3,4 -

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Reported Earlier, China's NMPA Approves Astellas' VYLOY (Zolbetuximab) For Advanced Gastric Cancer Treatment

Reported Earlier, China's NMPA Approves Astellas' VYLOY (Zolbetuximab) For Advanced Gastric Cancer Treatment

风险及免责提示

声明